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INTRODUCTION
Graft-versus-host disease (GVHD) is a major cause of
morbidity and mortality after allogeneic hematopoietic stem
cell transplantation. There is strong evidence that GVHD is
the result of donor T-cell recognition of endogenous minor
(MiHC) or major (MHC) histocompatibility antigens
expressed by recipient cells [1,2]. In humans, GVHD sec-
ondary to MiHC disparity results in clonal proliferation of
donor T-cells in vivo [3], and the presence of donor-derived
CD4+ and CD8+ T-cells in blood and marrow transplantation
(BMT) patients correlates with the development of GVHD
[4-7]. The primary therapeutic approach to control of GVHD
is the use of immunosuppressive agents. However, because
many of the immunosuppressive agents used to treat GVHD,
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ABSTRACT
The 4-aminoquinolines, chloroquine and hydroxychloroquine, are established, with a 52% response rate, as therapy
for human steroid-refractory GVHD after BMT. Chloroquine affects numerous mechanisms that play a role in
GVHD, including inhibition of major histocompatibility complex (MHC) class II antigen presentation, cytokine
production, and antigen-presenting cell activation by bacterially derived CpG oligodeoxynucleotides (ODNs). Using
an MHC-disparate murine model, we evaluated the effect of chloroquine treatment on the development of acute
GVHD. We assessed the effect of chloroquine on the immunostimulatory responses induced by CpG ODNs after
BMT. We also evaluated the impact of chloroquine on cytokine-producing populations known to affect GVHD,
including CD4+ and CD8+ T-cell and CD3+/NK1.1+ natural killer T-cell (NKT cell) populations. Twelve (86%) of
14 mice receiving phosphate-buffered saline solution (PBS) developed lethal GVHD; only 4 (29%) of 14 mice
receiving chloroquine 20 mg/kg 3 times per week developed lethal GVHD (P < .01). Chloroquine significantly sup-
pressed CpG ODN–induced splenic proliferation and interleukin 6 (IL-6) production associated with GVHD.
Chloroquine suppressed CD8+ T-cell production of IL-2 and IL-4 associated with GVHD in this model and main-
tained an early expansion (day 7) of splenic NKT cells. These results indicate that the 4-aminoquinolines are effec-
tive in therapy for or prevention of acute GVHD secondary to MHC disparities. Chloroquine actions may include
inhibition of CpG ODN augmentation of GVHD. Other mechanisms involved may include suppression of CD8+
T-cell production of IL-2 and IL-4 and an increase in NKT cells associated with GVHD inhibition by chloroquine.
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such as cyclosporine, tacrolimus, and steroids, are associated
with signiﬁcant toxicity [8], new agents with fewer side effects
and different mechanisms of action must be evaluated.
The immunosuppressive 4-aminoquinolines, chloro-
quine and hydroxychloroquine, are currently being investi-
gated for efﬁcacy against GVHD [9]. These drugs are well
established as therapy for autoimmune diseases such as sys-
temic lupus erythematosus and rheumatoid arthritis [10], and
they have a low toxicity proﬁle. These agents are weak bases
that affect acidification of lysosomes and endosomes, an
activity that results in the inhibition of MHC class II pro-
cessing and presentation [11]. In addition, these agents affect
release of proinﬂammatory cytokines such as interleukin 1
(IL-1), IL-6, and tumor necrosis factor α (TNF-α) [12];
inhibit cytotoxicity caused by T-cells [13]; induce apoptosis
in T-cells [14]; and, at high concentrations, block T-cell acti-
vation [15,16]. Our group has demonstrated that in murine
models chloroquine inhibits GVHD secondary to MiHC
antigen differences [17]. Chloroquine administration in vivo
inhibited the ability of antigen-presenting cells (APCs)
derived from treated mice to stimulate T-cells reactive
against MiHC [15] and MHC [12] antigens and inhibited
lipopolysaccharide (LPS)-induced MHC class II expression.
Both chloroquine and hydroxychloroquine have the added
beneﬁt that they are synergistic with cyclosporine, tacrolimus,
and rapamycin analogues [18,19]. A phase II clinical study
demonstrated that hydroxychloroquine therapy induced a
partial or complete response in 52% of 32 evaluable patients
with steroid-refractory chronic GVHD after BMT [20].
Hydroxychloroquine is now being evaluated in a phase III
multiinstitutional clinical trial in North America.
Although there is significant evidence to indicate that
the 4-aminoquinolines will be clinically effective against
GVHD, the mechanisms that underlie this activity remain
to be elucidated. Two distinct events that have recently been
reported to influence the development of GVHD would
appear to be potential targets for the action of these drugs.
First, unmethylated CpG oligodeoxynucleotides (ODN) in
bacterial DNA induce APCs to secrete IL-6 and IL-12 and
augment antigen presentation [21,22]. Recently, CpG
ODNs have been shown to increase the severity of GVHD
when used after BMT to augment antileukemia responses
[23]. Chloroquine can profoundly inhibit CpG ODN activ-
ity at concentrations easily attainable in vivo [24], a ﬁnding
that suggests the drug may suppress CpG ODN–induced
acceleration of GVHD. Second, acute GVHD in murine
MHC-disparate models has been associated with early pro-
duction of IL-2 and IL-4 by T-cells with amelioration of
acute GVHD severity by early interferon γ (IFN-γ) produc-
tion [25]. IL-4 production by NK1.1+/CD3+ natural killer
T-cells (NKT cells) also modulates GVHD [26]. Because
chloroquine can inhibit cytokine production, including IL-2
production in vivo [27], altered release of IL-2, IL-4, and
IFN-γ by chloroquine may impact GVHD development.
In this study we evaluated the therapeutic effect of chloro-
quine in an MHC-incompatible lethal GVHD murine
model. Our results indicated that chloroquine can suppress
the development of GVHD secondary to MHC disparities.
Chloroquine treatment has immunomodulatory effects,
significantly suppressing exaggerated GVHD-associated
splenic responses to CpG ODNs. In addition, chloroquine
suppressed CD8+ T-cell production of IL-2 and IL-4 associ-
ated with GVHD and maintained the early increase in NKT
cell populations observed in syngeneic control mice. These
findings support the further evaluation of 4-aminoquino-
lines as therapy for and prophylaxis of GVHD secondary to
differences in MHC (ie, mismatched-donor transplants) and




Six- to 8-week-old female C57BL/6 (H-2b), B10.BR
(H-2k), or BALB/c mice were obtained from Jackson Labo-
ratories (Bar Harbor, ME) and maintained in microisolator
cages in the animal care facility at the British Columbia
Research Institute for Children’s and Women’s Health.
Reagents
Chloroquine was purchased from Sigma Chemical Co
(St. Louis, MO). A fresh preparation of chloroquine in ster-
ile phosphate-buffered saline (PBS) was used in each experi-
ment at a ﬁnal concentration of 2 mg/mL (400 µg/200 µL)
for intraperitoneal (IP) injection. The stimulatory CpG
ODN 1760 has the sequence 5′-ATAATCGACGTTCAAG
CAAG-3′; the nonstimulatory ODN 1814 has the sequence
5′-ATAATCCAGCTTGAACCAAG-3′. Both were synthe-
sized with a phosphorothioate backbone and purchased
from Genosys (The Woodlands, TX).
Flow Cytometric Analysis
Mouse spleen and thymus were harvested, and single-
cell suspensions were prepared by passing the tissue through
nylon mesh. After red blood cell lysis, the suspension was
washed in PBS/2% fetal bovine serum (FBS). Cell labeling
was carried out on 1 × 105 cells in a 100-µL volume of
PBS/2% FBS at 4°C for 30 minutes with the following anti-
bodies (all antibodies were purchased from Pharmingen,
San Diego, CA.): anti–CD4-fluoroscein isothyocyanate
(FITC), anti–CD8-phycoerythrin (PE), anti–B220 PerCP,
anti–CD11c-PE, anti–NK-1.1-PE, and anti–CD3-FITC.
Cells were washed 3 times with 250 µL of PBS/2% FBS and
ﬁxed in 1.5% paraformaldehyde prior to analysis on a Bec-
ton Dickinson FACSCalibur system (Becton Dickinson, San
Jose, CA). For cytoplasmic staining, 1 × 106 cells per sample
of unstimulated cells were surface stained with CD4-
CyChrome, CD8-PE, CD3-FITC, B220-PerCP, CD11c-
PE, or NK1.1-PE for 30 minutes on ice. The cells were
then washed twice with PBS/2% FBS and fixed in 1.5%
paraformaldehyde for 10 minutes. After another wash with
PBS/2% FBS, the cells were permeabilized with Becton
Dickinson FACS permeabilization solution for 10 minutes
prior to addition of cytoplasmic antibodies (IL-2–APC, IL-4–
APC, and IFN-γ–APC [Pharmingen]). The cells were then
washed twice and analyzed immediately. Negative control
parameters were based on isotype control antibodies labeled
with the appropriate ﬂuorochrome.
Graft-versus-Host Model
Recipient B10.BR mice received chloroquine (10 or
20 mg/kg per dose) or an equal volume (200 µL) of PBS by
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IP injection daily for 5 days before transplantation and were
then irradiated with 950 cGy (total body) from a cesium-137
source 24 hours after the last dose. The chloroquine dose of
10 or 20 mg/kg per day is equivalent to a daily dose of 5.9 or
11.8 mg/kg per day of hydroxychloroquine [15]. In humans,
the therapeutic dose of hydroxychloroquine for systemic
lupus erythematosus is 6 mg/kg per day and for GVHD is
12 mg/kg per day [18]. Donor cells were obtained from the
spleen and bone marrow of C57BL/6 mice. Each of the irra-
diated B10.BR recipients was given an intravenous infusion
of 1.5 × 107 whole-population spleen cells and 2.5 × 107
bone marrow cells. After BMT, the groups received chloro-
quine or PBS (same doses as before BMT) IP 3 times per
week (Monday, Wednesday, and Friday) until the end of the
experiment. In addition to the PBS- and chloroquine-
treated groups, each experiment included a syngeneic con-
trol group (given infusions of spleen/bone marrow cells
from B10.DR donors) and an irradiation control group of
B10.BR mice that received irradiation alone to ensure that
the dose of irradiation was myeloablative. All irradiation
control mice died by day 20 posttransplantation. Engraft-
ment was monitored by immunophenotyping for H-2b
(donor) versus H-2k (recipient) in spleen, and, in selected
experiments in bone marrow, and was not signiﬁcantly dif-
ferent between the PBS- and chloroquine-treated groups.
Evaluation of GVHD was based on the clinical ﬁndings of
hunched appearance and wasting. Mice identiﬁed as having
GVHD were killed. In the indicated experiments, mice were
killed either 7 or 14 days after transplantation and were
evaluated histologically or by flow cytometry for changes
resulting from GVHD under different treatments. These
time points were based on those previously established in
this model as time points at which untreated or PBS-treated
mice are alive and immunological changes can be demon-
strated [28]. In these experiments the ﬁrst time of death for
PBS-treated mice was day 15.
CpG Oligodeoxynulceotide Stimulation of Spleen
Cells after BMT or Chloroquine Treatment
Spleens were removed on day 7 after BMT from mice
receiving a C57BL/6-into-B10.BR transplant. The spleen
cells were incubated in media alone, with a nonstimulatory
ODN sequence (ODN 1814) or with a stimulatory sequence
(ODN 1760) at 6 µg/mL as described previously [24]. [3H]-
thymidine incorporation was used to evaluate spleen cell
proliferation during the last 24 hours of a 3-day incubation.
The presence of IL-6 in the spleen cell culture supernatants
was assayed with an enzyme-linked immunoassay according
to the manufacturer’s protocol and with the standards sup-
plied (Pharmingen).
Experiments to evaluate the effect of CpG ODN 1780
injection were conducted with mice that have an optimal
CpG ODN response, BALB/c mice. BALB/c mice were
treated with PBS or 20 mg/kg of chloroquine for 5 days.
They then received 300 µg CpG ODN 1760 IP. Four hours
later, serum was removed and assayed for IL-6 and IL-12 by
enzyme-linked immunosorbent assay (ELISA) (pg/mL). For
exclusion of a nonspecific effect by chloroquine, an addi-
tional group (n = 2) received chloroquine with no CpG
ODN 1760 administration. Spleen cells were removed and
evaluated for cell populations by immunophenotyping.
Statistical Methods
Mean values and SEM of the counts per minute were
calculated with routine methods. Statistical signiﬁcance was
calculated with the unpaired Student t test on mean values
and the Fisher exact 2-tailed test for discrete variables.
RESULTS
Effect of Chloroquine Treatment on 
MHC-Disparate GVHD
The infusion of C57BL6 (H-2b) donor cells into
B10.BR (H-2k) recipients is an established model of acute
GVHD secondary to MHC disparity [28]. As expected, in
our experiments none of 8 mice receiving syngeneic donor
cells developed GVHD. Twelve (86%) of 14 mice receiving
PBS treatment after infusion of C57BL6 cells developed
GVHD (Figure 1A). Mice receiving 10 mg/kg chloroquine
3 times per week had a slight prolongation of survival, but
overall their outcome was similar to that of PBS-treated
mice. By contrast, only 4 (29%) of 14 mice receiving 20 mg/kg
chloroquine 3 times per week developed GVHD. This
result was a significant improvement over that for PBS-
treated mice (P = .01). The pattern of weight loss observed
for the different groups correlated with survival (Figure 1B).
Results of comparison of the weight loss in mice treated
with 20 mg/kg of chloroquine with the weight loss in mice
receiving syngeneic donor cells suggested that the mice
treated with chloroquine, although alive on day 60, had an
attenuation in the severity of GVHD rather than complete
abrogation. This result was conﬁrmed by histological evalu-
ation of the liver for evidence of GVHD. There was no
inﬁltration of lymphocytes in the syngeneic mice on day 14,
but there was intermediate inﬁltration in mice treated with
20 mg/kg chloroquine (data not shown). The PBS-treated
group had the most significant lymphocytic infiltration.
Donor cell engraftment was conﬁrmed in all BMT groups
by immunophenotyping of spleen cells (data not shown).
Effect of Chloroquine Treatment on Splenic
Responses to CpG ODNs
Splenic macrophages from mice with acute GVHD are
hyperresponsive to LPS stimulation in vitro [29]. We
hypothesized that a similar effect would be observed after
stimulation by CpG ODNs. To investigate this hypothesis,
we stimulated spleen cells from GVHD mice in vitro with
either the stimulatory CpG ODN 1760 or the nonstimula-
tory ODN 1814 and measured the resulting proliferative
response and IL-6 secretion. We observed that spleen cells
removed on day 7 from PBS-treated mice with GVHD had
both an exaggerated proliferative response and increased IL-6
production in response to ODN 1760 compared with the
results in cells from mice receiving a syngeneic BMT (Fig-
ures 2A and 2B). Both the proliferative (Figure 2A) and the
IL-6 (Figure 2B) responses induced in the PBS-treated
group by CpG ODN 1760 stimulation were significantly
higher (P = .05) than the responses in either the syngeneic or
the chloroquine-treated group. This enhanced response was
not observed when the cells were treated with ODN 1814 or
media alone, indicating that stimulatory CpG ODNs speciﬁ-
cally induced the activity. The decreased proliferation and IL-6
production seen in the syngeneic and chloroquine-treated
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groups could not be attributed to a decreased number of
either B-cells or CD11c+/Ia+ cells (Figure 2C).
Chloroquine previously has been shown to decrease IL-6
production after CpG ODN stimulation of B-cells in vitro
[24]. To ensure that the levels of chloroquine used to
inhibit the development of GVHD can decrease the CpG
response induced by GVHD, we evaluated the effect of
chloroquine treatment on induction of IL-6 production in
spleen cells after CpG administration. We used BALB/c
mice because they are established as having high responses
to CpG ODN stimulation. BALB/c mice (4 per group)
were treated with PBS or 20 mg/kg of chloroquine for
5 days. They then received 300 µg CpG ODN 1760 IP.
Four hours later, serum was prepared and assayed for IL-6
by ELISA (pg/mL). The chloroquine group had a signifi-
cant decrease in IL-6 production (Figure 2D) induced by
CpG ODN 1760 (P = .05). The level of IL-12 also was
lower in the chloroquine-treated group, but the difference
was not statistically different (P = .18). To rule out that
chloroquine treatment decreased IL-6 production by
decreasing the presence of either B-cells (B220+/Ia+) or
macrophage/dendritic cells (CD11c+/Ia+) we also pheno-
typed the spleens from the same mice (Figure 2E). We
observed no difference in the percentage of B-cells or
CD4+ or CD8+ T-cells between mice receiving chloroquine
and those treated with PBS. Chloroquine treatment inter-
estingly resulted in an increase in CD11c+ cells after CpG
ODN 1760 stimulation (P = .05).
Effect of Chloroquine Treatment on NK and NKT
Cell Populations
To determine the impact of chloroquine treatment on
NK and NKT cells, we performed quantitative analyses on
these cell populations in the spleen after BMT and, in the
case of NKT cells, determined the cytokine secretion pro-
ﬁles of the cells. In spleen on day 7, a signiﬁcant increase in
Figure 1. Effect of chloroquine treatment on survival and weight loss in a MHC-disparate GVHD model. B10.BR recipient mice were treated with
either chloroquine (10 or 20 mg/kg per dose) or PBS. Controls included a syngeneic BMT group in which B10.BR recipient mice received trans-
plants of B10.BR donor cells or 950 cGy irradiation alone with no donor cells infused. A, Survival curve with an event recorded as the day the mouse
was identiﬁed as having signiﬁcant GVHD and was killed. B, Weight was recorded 3 times per week (Monday, Wednesday, Friday) at the same time
as injection. These data represent the same mice as in Figure 1A. The curves represent the mean percentage of weight based on the transplantation
day weight (100%). The error bars represent SEM.
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Figure 2. Splenocyte proliferation in response to CpG ODN stimulation on day 7 after BMT. C57BL/6-into-B10.BR transplantation was per-
formed as previously described. Spleen cells were removed on day 7 post-BMT and incubated with media alone, ODN 1814, or ODN 1760 at
6 µg/mL. A, Proliferation was measured by [3H]-thymidine incorporation during the last 24 hours of a 3-day incubation. There were a total of 5 mice
per experimental group. B, IL-6 production was evaluated by ELISA analysis of the culture supernatant. There were a total of 5 mice per experi-
mental group. Both proliferation (A) and IL-6 production (B) were signiﬁcantly higher (P = .05) for the CpG ODN 1760–stimulated PBS group
than for the syngeneic and chloroquine groups. C, Percentage positivity for either CD11c–/B220+ or CD11c+/Ia+ cells was evaluated on day 7 post-
BMT. D, BALB/c mice (4 per group) were treated with PBS or 20 mg/kg of chloroquine for 5 days. They then received 300 µg CpG ODN 1760
IP. Four hours later, serum was prepared and assayed for IL-6 by ELISA (pg/mL). The difference was signiﬁcant (P = .05). For exclusion of a non-
speciﬁc effect by chloroquine, an additional group (n = 2) received chloroquine with no CpG ODN 1760 administration and did not have measur-
able IL-6 levels (not shown). The level of IL-12 also was lower in the chloroquine-treated group (not shown), but the difference was not statistically
different (P = .18). E, Spleen cells from mice identical to those in D were evaluated for cell populations. The numbers for B220+/Ia+ (B-cells),
CD11c+/Ia+ (macrophages and dendritic cells), CD3+/CD4+, and CD3+/CD8+ represent the percentage positivity of the entire spleen. * indicates a P
value of .05 measured with an unpaired t test and compared with the PBS control group.
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the number of NKT cells (P = .05) was observed in chloroquine-
treated mice compared with the number in syngeneic BMT
mice (Figure 3). In the PBS-treated mice, an increase in
NKT cells was not observed until day 14. NK cells were
increased in number in the spleens of syngeneic control
mice on both day 7 and day 14 but were not increased in
PBS- or chloroquine-treated mice (Figure 3). Analysis of the
cytokine expression proﬁles of splenic NKT cells revealed
that on day 7 there were only very low numbers of IL-4–
and INF-γ–producing cells in PBS-treated mice (data not
shown). In contrast, both syngeneic controls and chloroquine-
treated mice had elevated numbers of NKT cells producing
both IL-4 and INF-γ, although the difference was not
signiﬁcant (P = .12).
Chloroquine Treatment Resulted in Decreased IL-2
and IL-4 Production by CD8+ Splenic T-Cells on 
Days 7 and 14 after BMT 
Evaluation of the number of splenic CD4+ and CD8+
T-cells revealed an increased number of CD8+ T-cells in
chloroquine- and PBS-treated mice compared with the
number in syngeneic controls (data not shown). Increased
IL-2 production by both CD4+ and CD8+ splenic T-cells
was significantly higher (P = .05) in PBS-treated mice on
day 14 than it was in chloroquine-treated mice. IL-2 pro-
duction by both T-cell populations was suppressed by
chloroquine to levels similar to those in mice without
GVHD (Figure 4). Both PBS- and chloroquine-treated
mice had an increased number of IL-4–producing CD4+
cells on day 7 and day 14. However, only PBS-treated mice
contained IL-4–producing CD8+ cells. This ﬁnding indicated
that chloroquine treatment had decreased IL-4 production
in CD8+ T-cells but had no effect on IL-4 production by
CD4+ T-cells. IFN-γ production profiles were similar for
both PBS- and chloroquine-treated mice. TNF-α was eval-
uated in unstimulated T-cell and B-cell populations, and no
difference was seen between chloroquine- and PBS-treated
mice (data not shown).
DISCUSSION
In this study we demonstrated that chloroquine treatment
can decrease development of acute GVHD secondary to a full
disparity in MHC between the donor and recipient. Chloro-
quine therapy appeared to suppress rather than abrogate the
development of GVHD, as evidenced by the weight loss
observed in chloroquine-treated mice. With the treatment
regimen of 20 mg/kg per dose 3 times per week, the mice in
this report received an average daily dose of 8.6 mg/kg per
day. This dose is equivalent to 5 mg/kg per day of hydroxy-
chloroquine, approximately one-half the dose administered in
the phase II human GVHD trial. The ﬁndings in this report
support the conclusion that the 4-aminoquinolines may be
efficacious for patients who receive HLA-mismatched
hematopoietic stem cell transplants. In addition, these results
are the ﬁrst demonstration that chloroquine treatment alters
spleen cell responsiveness to CpG ODN stimulation and
Figure 3. Effect of chloroquine treatment on NK and NKT cell pop-
ulations. Mice receiving transplants identical to those described in Fig-
ure 1 were treated with PBS (n = 6), treated with chloroquine
(20 mg/kg per dose) (n = 7), or received a transplant from a syngeneic
(B10.BR) donor (n = 4). Total numbers of cells were counted per
spleen, and the populations were expressed as the mean number of cells
per spleen. The number of cells per spleen ((105 cell/spleen) for
NK1.1+/CD3+ (NKT cells) and NK1.1+/CD3– (NK cells) cells are pre-
sented for days 7 and 14. * indicates the only significant difference
according to the results of a t test between the syngeneic and chloroquine-
treated groups.
Figure 4. Evaluation of splenic T-cell populations. T-cell populations on day 7 and day 14 were selectively gated by CD4+ and CD8+ expression.
Production of IL-2, IL-4, and IFN-γ was evaluated by cytoplasmic staining of unstimulated spleen cells. The results are presented as mean number of
cells per spleen ±SEM ((105 cells/spleen). These analyses were performed on the same mice as in Figure 3. * indicates a signiﬁcant difference (P = .05)
compared with both the chloroquine and syngeneic treatment groups; **, a signiﬁcant difference compared with the syngeneic group.
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cytokine production by both T-cells and NKT cells in
MHC-disparate BMT recipients. These novel mechanisms
of action may contribute to the effectiveness of these drugs
against GVHD.
The ability of chloroquine to prevent the hyperrespon-
siveness to CpG ODN seen in GVHD mice is intriguing.
The release of the bacterially derived endotoxin LPS after
intestinal damage by the BMT preparative regimen (chemo-
therapy/irradiation) can accelerate GVHD in mouse mod-
els. LPS had been shown to induce macrophage priming
after BMT, the result being high levels of proliferation after
LPS stimulation in mice that have GVHD [29,30]. Antago-
nism of LPS decreases the severity of GVHD [31]. The
view that bacteria contribute to GVHD is consistent with
the fact that recurrences of GVHD are associated with
infection, and human antibacterial antibiotics decrease the
severity of acute GVHD [32]. CpG ODNs also are bacteri-
ally derived and have potent immunostimulatory abilities,
inducing APCs to secrete IL-6 and IL-12 and augment anti-
gen presentation [21,22]. CpG ODN signaling is mediated
by a speciﬁc CpG receptor, the Toll-like receptor 9 (TLR9)
[33,34]. A recent study demonstrated a wide tissue distribu-
tion of TLR9 expression, indicating that many cell types
may be responsive to stimulation by these bacterial products
[35]. It is interesting that the use of CpG ODN after allo-
geneic BMT, as an adjuvant for augmenting the graft-versus-
leukemia effect, appeared to accelerate the development of
GVHD [23]. It is known that chloroquine is a potent
inhibitor of CpG ODN–mediated stimulation of B-cells
[24]. Our data revealed that spleen cells from mice with
signiﬁcant GVHD are hyperresponsive to CpG ODN stim-
ulation compared with cells from syngeneic control mice.
These results demonstrate for the first time that in vivo
administration of chloroquine inhibits CpG ODN stimula-
tion of spleen cells from GVHD mice, suggesting that this
may be an important mechanism of action of this drug.
The results of our analysis of NK and NKT cells sug-
gested that chloroquine exerts an effect primarily on the latter
of these populations. The delayed onset of GVHD induced
with chloroquine treatment appeared to be associated with
the appearance of an IL-4–producing NKT cell population
on day 7 that disappeared by day 14, although the difference
was not enough to be statistically signiﬁcant. The kinetics of
this population were very similar to those observed in the
syngeneic control mice. Similarly, IFN-γ– producing NKT
cells were present on day 7 in the chloroquine-treated and
syngeneic mice but not in the PBS-treated mice. NKT cells
that express IFN-γ alone appear to be inﬂammatory, whereas
those that express both IL-4 and IFN-γ are suppressive
[36,37]. The IFN-γ–predominant population appears to be
associated with autoimmunity [38], and the IL-4–producing
NKT cells appear to have the ability to regulate T-cell reac-
tivity and induce tolerance [39,40]. Previous groups have
suggested a role for NKT cells (CD3+/NK1.1+) that predomi-
nantly produce IL-4 in suppression of GVHD [26]. Although
the exact mechanism by which chloroquine affects the pres-
ence of IL-4–producing NKT cells is unknown, the results
presented here suggest that this effect may underlie the inhi-
bition of GVHD and merit further investigation.
High levels of IL-2 and IL-4 soon after BMT have been
well characterized after MHC-disparate BMT in murine
models [25]. Chloroquine significantly inhibited sponta-
neous IL-2 production by both CD4+ and CD8+ T-cells on
day 14 compared with the effect in PBS-treated mice.
Chloroquine also significantly inhibited IL-4 production
by CD8+ T-cells post-BMT but had no inﬂuence on CD4+
T-cells. The presence of IFN-γ soon after BMT in these
models has been reported to inhibit the development of
GVHD, but we saw little evidence of spontaneous IFN-γ
production by these splenic populations. These data indicate
that the inﬂuence of chloroquine on cytokine production is
generally in the direction predicted to alleviate GVHD.
Although obviously not deﬁnitive, the results again suggest
that this is an important activity of the drug.
In conclusion, these studies show that chloroquine treat-
ment is sufﬁcient to delay the onset of GVHD secondary to
MHC disparities. Chloroquine was a potent inhibitor of
GVHD-associated exaggerated splenic responses induced by
CpG ODN. This finding suggests both a role of CpG
ODNs in acute GVHD and a novel mechanism of action by
chloroquine in suppression of GVHD. Chloroquine treat-
ment also appeared to result in an early increase of splenic
NKT cells that produced IL-4 and a reduction of IL-2 and
IL-4 production by CD8+ T-cells. The results of these stud-
ies support the evaluation of hydroxychloroquine in thera-
peutic trials and further studies to determine its therapeutic
effects on immune populations important in GVHD.
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